Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Latest Market Insights for the Ticagrelor Industry?
The market size for ticagrelor has experienced robust growth in the past few years. The market is predicted to expand from $1.79 billion in 2024 to $1.93 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.6%. The surge in growth during the historical period is largely due to the escalating occurrence of cardiovascular diseases, an increasing elderly population, heightened knowledge about heart health, advancements in pharmaceutical research, and the uptick in incidence of acute coronary syndrome.
In the forthcoming years, the market size of ticagrelor is anticipated to observe robust growth, reaching a valuation of $2.57 billion by 2029 at a compound annual growth rate (CAGR) of 7.4%. The propulsion in growth during the projected timeline can be credited to the increasing implementation of personalized medicine, higher spending in the healthcare sector, surging demand for treatments that are minimally invasive, heightened focus on preventive cardiology, and government-driven initiatives specifically for cardiac care. The anticipated trends within the forecast period encompass personalized medicine advancements, the launch of generic ticagrelor, the fusion of artificial intelligence in the development of drugs, the invention of next-generation antiplatelet drugs, and emphasis on patient adherence through fixed-dose mixtures.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24726&type=smp
What Forces Are Driving The Growth Of The Ticagrelor Industry?
The upward trend in cardiovascular diseases is set to stimulate expansion in the ticagrelor market. Often, cardiovascular illnesses comprise of a range of disorders affecting one’s heart and blood vessels. Among these conditions are coronary heart disease, heart failure, stroke, and hypertension. These diseases are generally caused by unhealthy diet habits, including excessive consumption of saturated fats, trans fats, sugars, and sodium. All of these dietary aspects lead to high blood pressure, obesity and high cholesterol levels, which are major contributors to heart-related conditions. Ticagrelor comes into play by treating cardiovascular diseases through the prevention of platelet aggregation, thereby mitigating the risk of blood clot formation. This enhances patient results by diminishing the likelihood of heart attacks and strokes, predominantly in high-risk individuals. To illustrate, data from the American Heart Association, a US-based philanthropic entity, reveals that the age-oriented death rate from cardiovascular diseases swelled to 233.3 per 100,000 in 2022 from 224.4 per 100,000 in 2021 — an increase of 4.0% . Consequently, the mounting prevalence of cardiovascular diseases is energizing the ticagrelor market’s growth.
What Is The Overview Of Market Segmentation In The Ticagrelor Industry?
The ticagrelor market covered in this report is segmented –
1) By Type: 90 mg Tablet, 60 mg Tablet
2) By Drug Class: Antiplatelet Agents, Antithrombotic Agents
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Acute Coronary Syndrome, Myocardial Infarction, Stroke Prevention, Other Applications
5) By End User: Hospitals And Clinics, Ambulatory Centers, Other End Users
Subsegments:
1) By 90 Mg Tablet: Standard 90 Mg Ticagrelor Tablet, Extended-Release 90 Mg Ticagrelor Tablet
2) By 60 Mg Tablet: Standard 60 Mg Ticagrelor Tablet, Extended-Release 60 Mg Ticagrelor Tablet
What Future Market Trends Are Projected For The Ticagrelor Industry?
Key players in the ticagrelor market are striving to acquire regulatory certifications to boost their product indications, widen their market reach, and enhance their competitive edge. These certifications are given by public governing bodies, implying that the product has met the requisite safety, efficiency, and quality benchmarks. For example, Alembic Pharmaceuticals Ltd., an Indian-based pharma firm, was granted an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) in May 2025 for their generic ticagrelor tablets of 90 mg and received a provisional approval for the 60 mg variant. These tablets help mitigate the chances of cardiovascular complications by inhibiting platelet aggregation and thus, preventing blood clot formation.
Who Are The Primary Players Operating Across The Global Ticagrelor Market?
Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/ticagrelor-global-market-report
Which Region Offers The Most Growth Potential For The Ticagrelor Market Through 2029?
North America was the largest region in the ticagrelor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24726&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model